Edition:
United Kingdom

Galmed Pharmaceuticals Ltd (GLMD.OQ)

GLMD.OQ on NASDAQ Stock Exchange Capital Market

5.57USD
23 Feb 2018
Change (% chg)

$0.17 (+3.15%)
Prev Close
$5.40
Open
$5.33
Day's High
$5.66
Day's Low
$5.33
Volume
11,546
Avg. Vol
16,965
52-wk High
$12.00
52-wk Low
$3.61

Chart for

About

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product candidate,... (more)

Overall

Beta: 2.60
Market Cap(Mil.): $117.83
Shares Outstanding(Mil.): 12.64
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.60
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Galmed Announces Arrive Study Data

* TOP-LINE RESULTS FROM ARRIVE TRIAL DID NOT MEET ITS PRIMARY ENDPOINT

14 Feb 2018

BRIEF-Galmed Pharmaceuticals To Provide Corporate Update At The Leerink Partners 7Th Annual Global Healthcare Conference

* GALMED PHARMACEUTICALS TO PROVIDE CORPORATE UPDATE AT THE LEERINK PARTNERS 7TH ANNUAL GLOBAL HEALTHCARE CONFERENCE Source text for Eikon: Further company coverage:

08 Feb 2018

BRIEF-Israeli Tax Authority Issues Tax Ruling On Galmed Pharma's Unit

* GALMED PHARMACEUTICALS -ISRAELI TAX AUTHORITY ISSUED TAX RULING GRANTING CO'S UNIT "PREFERRED TECHNOLOGICAL ENTERPRISE" STATUS, SUBJECT TO CONDITIONS

07 Feb 2018

BRIEF-Galmed Pharma Raised Gross Proceeds Of $11.6 Mln Under ATM Programs During Dec. 2017

* GALMED PHARMACEUTICALS RAISED GROSS PROCEEDS OF $11.6 MILLION UNDER ATM PROGRAMS DURING DECEMBER 2017 Source text for Eikon: Further company coverage:

02 Jan 2018

BRIEF-683 Capital Management Llc Reports 5.1 Pct Passive Stake In Galmed Pharmaceuticals Ltd As Of Dec 6

* 683 CAPITAL MANAGEMENT LLC REPORTS 5.1 PERCENT PASSIVE STAKE IN GALMED PHARMACEUTICALS LTD AS OF DEC 6 - SEC FILING Source text: (http://bit.ly/2oG4CRl) Further company coverage:

18 Dec 2017

BRIEF-Galmed Pharmaceuticals Q3 loss per share $0.23

* Galmed Pharmaceuticals reports third quarter 2017 financial results and provides business update

09 Nov 2017

BRIEF-Galmed Pharmaceuticals announces ‍publication of a paper entitled "role of aramchol in steatohepatitis and fibrosis in mice"

* Galmed Pharmaceuticals Ltd - ‍publication of a paper entitled "role of aramchol in steatohepatitis and fibrosis in mice" in hepatology communications

05 Oct 2017

Earnings vs. Estimates